Document is current
Any future updates will be listed below
-
Authors
Ukashi, Offir
Dotan, Arad
Borkovsky, Tom
Talan Asher, Adi
Thurm, Tamar
Hirsch, Ayal
Maharshak, Nitsan
Niv, Eva
Leshno, Moshe
Eliakim, Rami
Ben-Horin, Shomron
Kopylov, Uri
Deutsch, Liat
-
Funding
Funding for this research was provided by:
Tel Aviv University
- License Information
-
More Information
Article History
Received: 5 September 2024
Accepted: 26 September 2024
First Online: 9 October 2024
Declarations
:
: Shomron Ben-Horin has received Advisory board and/or consulting fees from Abbvie, Takeda, Janssen, Celltrion, Pfizer, GSK, Ferring, Novartis, Roche, Gilead, NeoPharm, Predicta Med, Galmed, Medial Earlysign, BMS and Eli Lilly, holds stocks/options in Predicta Med, Evinature & Galmed, and received research support from Abbvie, Takeda, Janssen, Celltrion, Pfizer, & Galmed. Uri Kopylov received speaker and advisory fees: Abbvie, BMS, Celtrion, Janssen, Medronic, Pfizer, Roche, Takeda, Elly Lili, research support: Janssen, Medtronic, Takeda, Elly Lili Abbvie BMS. Rami Eliakim received consultant and speaker fees from Janssen, Abbvie, Takeda and Medtronic. Eva Niv received consultant fees from Medtronic. Nitsan Maharshak has received speaking and/ or consulting fees from Pfizer, Abbvie, Lilly, Takeda, Janssen, Ferring, BiomX, BMS, Nestle, Trobix Innovation, Teva and grant support from Takeda, Janssen, Abbott, Abbvie, Pfizer, BMS, Corundum Innovation Ltd, Nestle. Ayal Hirsch has received speaking honoraria from Perigo, Padagis, Janssen, Abbvie, Takeda and received grants from Janssen, Takeda and Abbvie. Tamar Thurm has received lecture fee from Takada. Liat Deutsch has previously received payment for consulting and/or lecturing services from Medtronic, Neopharm, Abbott, Abbvie, and Fresenius Kabi. The remaining authors (Offir Ukashi, Arad Dotan, Tom Borkovsky, Adi Talan Asher, Moshe Leshno) declare that they have no conflicts of interest.
: This study was carried out in accordance with the ethical guidelines of the Declaration of Helsinki. The study was approved by the Sheba Medical Center ethics committee and the Tel-Aviv Sourasky Medical Center ethics committee. Approval was granted for Helsinki protocol SMC-13-0218 (July 2nd, 2013), SMC-18-4945 (June 26th, 2018) and TLV-0032-23 (March 26th, 2023) and TLV-0292-19 TLV-0292-19 (Sep. 4th, 2019). Since this was a retrospective case–control study, no informed consent was obtained for this specific analysis. However, informed consent was obtained from patients who were part of the prospective cohorts of this study.
